Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin Infusion Rate for Plasma Volume Expansion (AIR)
NCT02728921Phase 4Completed
- Sponsor
- Region Skåne
- Start
- Apr 2014
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of albumin (human) in hypovolemia and Systemic Inflammatory Response Syndrome (SIRS), sponsored by Region Skåne. Primary endpoint: Change in plasma volume at 3 hours. Started Apr 2014; status: completed.
02
Drugs
albumin (human)
03
Conditions
hypovolemiaSystemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT02728921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728921.